Drug Eluting Stent Current Events | Drug Eluting Stent News
|
| Page
1 of
30 |
598 Results |
|
|
|
Sort By:
Page Views | Date |
Early reports of thrombosis after insertion of drug-eluting stent (pp 1466, 1519)
Authors of a research letter in this week's issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy. view more (2004-10-20)
Risk and outcome similar for bypass surgery, drug-eluting stents
Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. view more (2007-04-20)
Better patient outcomes with drug eluting stents
Patients receiving drug eluting stents (DES) - stents coated with medication to prevent narrowing of the artery - as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ http://www.cmaj.ca/press/080050.pdf. view more (2008-12-18)
SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved... view more... (2009-09-24)
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine. view more (2008-05-23)
Fewer adverse cardiac events at one year
Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the... view more... (2007-10-24)
Drug-eluting stents more effective, equally as safe as bare metal stents in clinical trial
Late-breaking data from the HORIZONS AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction) trial reveal that after one year, use of a drug-eluting (paclitaxel) stent demonstrated significantly reduced rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of... view more... (2008-10-16)
Comparison of drug-releasing coronary stents show similar effectiveness
Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in the February 22 issue of JAMA. view more (2006-02-22)
Drug-eluting stents prove more effective, equally as safe as bare-metal stents
The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine. view more (2009-05-07)
The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac... view more... (2008-03-14)
Best use of drug-eluting stents
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. view more (2008-09-02)
ESC Congress 2003: New drug-eluting stents: enthusiasm sobered by economic constraints
IMPORTANT: This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology ESC Congress 2003: Drug-eluting stents - a universal panacea A huge wave of... view more... (2003-09-02)
NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. view more (2009-05-27)
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the... view more... (2009-09-28)
Drug-eluting stents may cause allergic reactions
Drug-eluting stents have greatly reduced the risk of repeat blockage of heart arteries, but researchers from Northwestern Memorial Hospital have found that in some patients, the stents can cause allergic reactions that can have serious consequences. view more (2005-12-20)
Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
A study showing that diabetic patients who are treated with long-term anti-clotting therapy are less likely to have a heart attack or die more than a year after stenting has been named among the best research papers presented at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12,... view more... (2007-05-18)
Promising 3-year data: Saving limbs with drug-eluting stents
Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene)... view more... (2009-03-10)
Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. view more (2008-12-18)
Value of stent-coating drugs questioned
Patients admitted to the hospital with acute coronary syndromes (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention (PCI), during which a stent is inserted into an occluded or narrowed coronary artery to restore blood flow to and from the heart. view more (2007-03-27)
Medication-releasing stent reduces risk of artery re-narrowing following angioplasty
Compared to bare metal stents, placement of stents that release the medication paclitaxel reduces the risk of the artery re-narrowing nine months following angioplasty for patients with complex coronary artery lesions. view more (2005-09-14)
|
|
| Page
1 of
30 |
598 Results |
|
|
|
Sort By:
Page Views | Date |
|
